The difference between ametinib and osimertinib

Almonertinib and Osimertinib/Osimertinib are two targeted treatments for advanced non-small cell lung cancer (NSCLC), but they have some differences in their mechanisms of action, drug characteristics and clinical applications.

1.Mechanism of action:

Ametinib: is an oral third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor that highly selectively inhibits EGFR activity. It is mainly used to treat patients with EGFR T790M mutation-positive NSCLC, a common EGFR drug-resistant mutation. Ametinib blocks the proliferation and survival of tumor cells by inhibiting the activity of EGFR.

Osimertinib/Osimertinib: It is also a third-generation EGFRtyrosine kinase inhibitor, but it has higher specificity and is mainly used to treat EGFR Del19, L858R and T790M mutation-positive NSCLC patients. Osimertinib/Osimertinib effectively inhibits tumor proliferation and metastasis by inhibiting EGFR activity.

2.Resistance and mutation spectrum:

Ametinib: Mainly used to treatEGFR T790Mpositive drug resistanceNSCLC, targeting this specific drug resistance mutation.

Osimertinib/Osimertinib: In addition to targeting EGFR T790Mpositive drug resistanceNSCLC, it can also treat EGFR Del19, L858R and T790M positive NSCLC and therefore have a wider range of indications.

3.Clinical efficacy:

Clinical trials have shown that ametinib has good efficacy in EGFR T790Mpositive drug-resistant NSCLC patients, significantly extending the patient's survival.

Osimertinib/OsimertinibatEGFR Del19, L858R and T790M positive NSCLC patients also showed significant efficacy, compared with standard treatment, can significantly extend the progression-free survival and overall survival of patients.

4.Side effects:

The two drugs differ in terms of side effects, but common adverse reactions include rash, diarrhea, drowsiness, fatigue, cough, and more.

Severe adverse reactions may include interstitial pneumonitis, cardiovascular events, visual impairment, etc., but the specific incidence and severity may vary depending on individual patient differences.

5.Medication guidance:

Ametinib is an important treatment option for patients with EGFR T790Mpositive drug-resistant NSCLC.

ForEGFR Del19, L858R and T790MpositiveNS For CLCpatients, osimertinib/osimertinib may be a more suitable treatment drug.

In summary, although ametinib and osimertinib/osimertinib are targeted therapeutic drugs for EGFR mutation-positive NSCLC, they have some differences in their mechanisms of action, indications and clinical applications. Choosing an appropriate treatment regimen should be an individualized decision based on the patient's specific situation and mutation spectrum.